Best Options Strategy for IONS
Looking for the best options strategy for Ionis Pharmaceuticals, Inc. (IONS)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live IONS option chain right now, and a simple map from your view on IONS to the strategy that fits it. Model any of them in the calculator before you trade.
About IONS
Ionis Pharmaceuticals, Inc. (IONS) is a major company in Biotechnology. Options traders on IONS tend to watch , since these can drive large moves in the share price.
About Ionis Pharmaceuticals, Inc.
# About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is a biotechnology company that develops and commercializes medicines designed to target RNA. The company's approved products address rare genetic and neurological diseases. SPINRAZA treats spinal muscular atrophy in children and adults, while WAINUA and TEGSEDI address hereditary transthyretin amyloidosis affecting the nervous system. The company also markets TRYNGOLZA for a rare lipid disorder called familial chylomicronemia syndrome, DAWNZERA to prevent attacks of hereditary angioedema, QALSODY for amyotrophic lateral sclerosis, and WAYLIVRA for lipid metabolism disorders. Beyond its marketed drugs, Ionis maintains a substantial pipeline of investigational medicines, including several in Phase 3 trials targeting conditions like severe hypertriglyceridemia, Alexander disease, and other rare neurological disorders.
The company generates revenue primarily from sales of its approved medications in the United States market. Ionis operates partnerships to extend its reach and capabilities, including a strategic collaboration with Biogen focused on neurological disease treatments. The company's business model relies on…
Today's top-scoring strategy for IONS
Our engine ranks defined-risk strategies on the live IONS chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $65 | $0.60 |
| Sell | 1× | PUT | $72.5 | $0.75 |
| Sell | 1× | CALL | $87.5 | $1.48 |
| Buy | 1× | CALL | $95 | $0.40 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Live scan from 2026-07-02 · quotes delayed ~15 minutes
Implied volatility
IONS is currently trading with elevated implied volatility, so its options carry richer premiums. On the options we scanned that was around 49% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on IONS currently price in about 49% implied volatility, versus roughly 25% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.
Off that volatility, the options market is pricing a move of about ±$7.79 (±10%) in IONS by 2026-07-17 — a range of roughly $72.41 to $88. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on IONS trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
Liquidity and tradeability
IONS options are thinly traded, with wide bid-ask spreads around 31.1% near the money that eat into any edge — favour simple single-leg or tight defined-risk trades, and always use limit orders.
Earnings & IV crush
IONS's next earnings report is due around August 5, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $13.5B
- Beta (vs market)
- 0.37
- 52-week range
- $40.03–$86.74 (86% up the range)
- Short interest
- 14.3% of float · 10.3 days to cover
With 14.3% of IONS's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for IONS
Start with your outlook on IONS, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while IONS stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open IONS in the free calculator →
Frequently asked questions
What is the best options strategy for IONS?
It depends on your outlook. Bullish traders often use a long call or bull call spread on IONS; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are IONS options liquid enough to trade?
Ionis Pharmaceuticals, Inc. (IONS) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade IONS options?
Buying a single IONS call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade IONS or any security. Do your own research.
What does Ionis Pharmaceuticals, Inc. do?
Ionis Pharmaceuticals, Inc. (IONS) operates in the Biotechnology industry. The "About Ionis Pharmaceuticals, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Ionis Pharmaceuticals, Inc. pay a dividend?
Ionis Pharmaceuticals, Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
When does Ionis Pharmaceuticals, Inc. next report earnings?
Ionis Pharmaceuticals, Inc.'s next earnings are expected around August 5, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to IONS
Comparing IONS with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 2855 Gazelle Court, Carlsbad, CA, 92010, United States
- Industry
- Biotechnology
- Employees
- 1,402
- CEO
- Dr. Brett P. Monia Ph.D.
- Phone
- 760 931 9200
- Website
- www.ionis.com
- Investor relations
- ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-irhome
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.